Fungal Infection in Lung Transplantation

Abstract

Invasive fungal infections threaten lung transplant outcomes with high associated morbidity and mortality. Pharmacologic prophylaxis may be key to prevent posttransplant invasive fungal infections, but cost, adverse effects, and absorption issues are barriers to effective prophylaxis. Trends in fungal infection diagnostic strategies utilize molecular diagnostic methodologies to complement traditional histopathology and culture techniques. While lung transplant recipients are susceptible to a variety of fungal pathogens, Candida spp. and Aspergillus spp. infections remain the most common. With emerging resistant organisms and multiple novel antifungal agents in the research pipeline, it is likely that treatment strategies will continue to evolve.

Keywords

lung transplant - fungal infection - immunocompromised - antifungal prophylaxis

Publikationsverlauf

Artikel online veröffentlicht:
24. Mai 2021

• References

• 1 Arthurs SK, Eid AJ, Deziel PJ. et al. The impact of invasive fungal diseases on survival after lung transplantation. Clin Transplant 2010; 24 (03) 341-348
• 2 Bhaskaran A, Mumtaz K, Husain S. Anti-Aspergillus prophylaxis in lung transplantation: a systematic review and meta-analysis. Curr Infect Dis Rep 2013; 15 (06) 514-525
• 3 Cornely OA, Hoenigl M, Lass-Flörl C. et al; Mycoses Study Group Education and Research Consortium (MSG-ERC) and the European Confederation of Medical Mycology (ECMM). Defining breakthrough invasive fungal infection—position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. Mycoses 2019; 62 (09) 716-729
• 4 Doligalski CT, Benedict K, Cleveland AA. et al. Epidemiology of invasive mold infections in lung transplant recipients. Am J Transplant 2014; 14 (06) 1328-1333
• 5 Vazquez R, Vazquez-Guillamet MC, Suarez J, Mooney J, Montoya JG, Dhillon GS. Invasive mold infections in lung and heart-lung transplant recipients: Stanford University experience. Transpl Infect Dis 2015; 17 (02) 259-266
• 6 Ashraf N, Kubat RC, Poplin V. et al. Re-drawing the maps for endemic mycoses. Mycopathologia 2020; 185 (05) 843-865
• 7 Maphanga TG, Birkhead M, Muñoz JF. et al. Human blastomycosis in South Africa caused by Blastomyces percursus and Blastomyces emzantsi sp. nov., 1967 to 2014. J Clin Microbiol 2020; 58 (03) 58
• 8 Oltean HN, Springer M, Bowers JR. et al. Suspected locally acquired coccidioidomycosis in human, Spokane, Washington, USA. Emerg Infect Dis 2020; 26 (03) 606-609
• 9 Lestrade PPA, Buil JB, van der Beek MT. et al. Paradoxal trends in azole-resistant Aspergillus fumigatus in a national multicenter surveillance program, the Netherlands, 2013-2018. Emerg Infect Dis 2020; 26 (07) 1447-1455
• 10 Zhang J, Lopez Jimenez L, Snelders E. et al. Dynamics of Aspergillus fumigatus in azole fungicide-containing plant waste in the Netherlands (2016-2017). Appl Environ Microbiol 2021; 87 (02) e02295-e20
• 11 Baddley JW, Marr KA, Andes DR. et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009; 47 (10) 3271-3275
• 12 Delbove A, Alami H, Tissot A. et al. Pneumocystis pneumonia after lung transplantation: a retrospective multicenter study. Respir Med 2020; 169: 106019
• 13 Neoh CF, Snell GI, Kotsimbos T. et al. Antifungal prophylaxis in lung transplantation--a world-wide survey. Am J Transplant 2011; 11 (02) 361-366
• 14 Pennington KM, Yost KJ, Escalante P, Razonable RR, Kennedy CC. Antifungal prophylaxis in lung transplant: a survey of United States' transplant centers. Clin Transplant 2019; 33 (07) e13630
• 15 Pennington KM, Baqir M, Erwin PJ, Razonable RR, Murad MH, Kennedy CC. Antifungal prophylaxis in lung transplant recipients: a systematic review and meta-analysis. Transpl Infect Dis 2020; 22 (04) e13333
• 16 Pennington KM, Razonable RR, Peters S. et al. Why do lung transplant patients discontinue triazole prophylaxis?. Transpl Infect Dis 2019; 21 (03) e13067
• 17 Pennington KM, Dykhoff HJ, Yao X. et al. The impact of antifungal prophylaxis in lung transplant recipients. Ann Am Thorac Soc 2021; 18 (03) 468-476
• 18 Neoh CF, Snell GI, Levvey B. et al. Preemptive treatment with voriconazole in lung transplant recipients. Transpl Infect Dis 2013; 15 (04) 344-353
• 19 Pilarczyk K, Haake N, Heckmann J. et al. Is universal antifungal prophylaxis mandatory in adults after lung transplantation? A review and meta-analysis of observational studies. Clin Transplant 2016; 30 (12) 1522-1531
• 20 Lass-Flörl C, Aigner M, Nachbaur D. et al. Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: a 12-year experience. Infection 2017; 45 (06) 867-875
• 21 Bart-Delabesse E, Basile M, Al Jijakli A. et al. Detection of Aspergillus galactomannan antigenemia to determine biological and clinical implications of beta-lactam treatments. J Clin Microbiol 2005; 43 (10) 5214-5220
• 22 Castagnola E, Machetti M, Bucci B, Viscoli C. Antifungal prophylaxis with azole derivatives. Clin Microbiol Infect 2004; 10 (Suppl. 01) 86-95
• 23 Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42 (10) 1417-1427
• 24 Park SY, Lee SO, Choi SH. et al. Aspergillus galactomannan antigen assay in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Infect 2010; 61 (06) 492-498
• 25 Bergeron A, Belle A, Sulahian A. et al. Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Chest 2010; 137 (02) 410-415
• 26 Guo YL, Chen YQ, Wang K, Qin SM, Wu C, Kong JL. Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review. Chest 2010; 138 (04) 817-824
• 27 Heng SC, Morrissey O, Chen SC. et al. Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: a systematic review and meta-analysis. Crit Rev Microbiol 2015; 41 (01) 124-134
• 28 Luong ML, Filion C, Labbé AC. et al. Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patients with hematologic malignancies. Diagn Microbiol Infect Dis 2010; 68 (02) 132-139
• 29 Racil Z, Kocmanova I, Toskova M. et al. Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases-the role of factors affecting assay performance. Int J Infect Dis 2011; 15 (12) e874-e881
• 30 Nucci M, Carlesse F, Cappellano P. et al. Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing. PLoS One 2014; 9 (01) e87784
• 31 Busca A, Locatelli F, Barbui A. et al. Usefulness of sequential Aspergillus galactomannan antigen detection combined with early radiologic evaluation for diagnosis of invasive pulmonary aspergillosis in patients undergoing allogeneic stem cell transplantation. Transplant Proc 2006; 38 (05) 1610-1613
• 32 Obayashi T, Yoshida M, Mori T. et al. Plasma (1-->3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345 (8941): 17-20
• 33 Hage CA, Carmona EM, Evans SE, Limper AH, Ruminjo J, Thomson CC. Summary for clinicians: microbiological laboratory testing in the diagnosis of fungal infections in pulmonary and critical care practice. Ann Am Thorac Soc 2019; 16 (12) 1473-1477
• 34 Bansal N, Gopalakrishnan R, Sethuraman N. et al. Experience with β-D-glucan assay in the management of critically ill patients with high risk of invasive candidiasis: an observational study. Indian J Crit Care Med 2018; 22 (05) 364-368
• 35 Posteraro B, Tumbarello M, De Pascale G. et al. (1,3)-β-D-glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study. J Antimicrob Chemother 2016; 71 (08) 2262-2269
• 36 Tran T, Beal SG. Application of the 1,3-β-D-glucan (Fungitell) assay in the diagnosis of invasive fungal infections. Arch Pathol Lab Med 2016; 140 (02) 181-185
• 37 Wood BR, Komarow L, Zolopa AR, Finkelman MA, Powderly WG, Sax PE. Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms. AIDS 2013; 27 (06) 967-972
• 38 Cruciani M, Mengoli C, Loeffler J. et al. Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. Cochrane Database Syst Rev 2015; CD009551
• 39 Springer J, Goldenberger D, Schmidt F. et al. Development and application of two independent real-time PCR assays to detect clinically relevant Mucorales species. J Med Microbiol 2016; 65 (03) 227-234
• 40 Avni T, Levy I, Sprecher H, Yahav D, Leibovici L, Paul M. Diagnostic accuracy of PCR alone compared to galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis: a systematic review. J Clin Microbiol 2012; 50 (11) 3652-3658
• 41 Neely LA, Audeh M, Phung NA. et al. T2 magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood. Sci Transl Med 2013; 5 (182) 182ra54
• 42 Mylonakis E, Clancy CJ, Ostrosky-Zeichner L. et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis 2015; 60 (06) 892-899
• 43 Clancy CJ, Nguyen MH. Diagnosing invasive candidiasis. J Clin Microbiol 2018; 56 (05) e01909-e01917
• 44 Walker B, Powers-Fletcher MV, Schmidt RL, Hanson KE. Cost-effectiveness analysis of multiplex PCR with magnetic resonance detection versus empiric or blood culture-directed therapy for management of suspected candidemia. J Clin Microbiol 2016; 54 (03) 718-726
• 45 Durkin M, Witt J, Lemonte A, Wheat B, Connolly P. Antigen assay with the potential to aid in diagnosis of blastomycosis. J Clin Microbiol 2004; 42 (10) 4873-4875
• 46 Bariola JR, Hage CA, Durkin M. et al. Detection of Blastomyces dermatitidis antigen in patients with newly diagnosed blastomycosis. Diagn Microbiol Infect Dis 2011; 69 (02) 187-191
• 47 Frost HM, Novicki TJ. Blastomyces antigen detection for diagnosis and management of blastomycosis. J Clin Microbiol 2015; 53 (11) 3660-3662
• 48 Fandiño-Devia E, Rodríguez-Echeverri C, Cardona-Arias J, Gonzalez A. Antigen Detection in the Diagnosis of Histoplasmosis: A Meta-analysis of Diagnostic Performance. Mycopathologia 2016; 181 (3-4): 197-205
• 49 Richer SM, Smedema ML, Durkin MM. et al. Improved diagnosis of acute pulmonary histoplasmosis by combining antigen and antibody detection. Clin Infect Dis 2016; 62 (07) 896-902
• 50 Klein BS, Vergeront JM, Weeks RJ. et al. Isolation of Blastomyces dermatitidis in soil associated with a large outbreak of blastomycosis in Wisconsin. N Engl J Med 1986; 314 (09) 529-534
• 51 Richer SM, Smedema ML, Durkin MM. et al. Development of a highly sensitive and specific blastomycosis antibody enzyme immunoassay using Blastomyces dermatitidis surface protein BAD-1. Clin Vaccine Immunol 2014; 21 (02) 143-146
• 52 Malo J, Holbrook E, Zangeneh T. et al. Enhanced antibody detection and diagnosis of coccidioidomycosis with the Miravista IgG and IgM detection enzyme immunoassay. J Clin Microbiol 2017; 55 (03) 893-901
• 53 Lortholary O, Renaudat C, Sitbon K. et al; French Mycosis Study Group. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med 2014; 40 (09) 1303-1312
• 54 Andes DR, Safdar N, Baddley JW. et al; Mycoses Study Group. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54 (08) 1110-1122
• 55 Chamilos G, Luna M, Lewis RE. et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91 (07) 986-989
• 56 Carneiro HA, Coleman JJ, Restrepo A, Mylonakis E. Fusarium infection in lung transplant patients: report of 6 cases and review of the literature. Medicine (Baltimore) 2011; 90 (01) 69-80
• 57 Roden MM, Zaoutis TE, Buchanan WL. et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41 (05) 634-653
• 58 Stewart JI, D'Alonzo GE, Ciccolella DE, Patel NB, Durra H, Clauss HE. Reverse halo sign on chest imaging in a renal transplant recipient. Transpl Infect Dis 2014; 16 (01) 115-118
• 59 Wand O, Unterman A, Izhakian S, Fridel L, Kramer MR. Mucormycosis in lung transplant recipients: a systematic review of the literature and a case series. Clin Transplant 2020; 34 (02) e13774
• 60 Marek C, Croxen MA, Dingle TC. et al. The use of genome sequencing to investigate an outbreak of hospital-acquired mucormycosis in transplant patients. Transpl Infect Dis 2019; 21 (05) e13163
• 61 Chaves MS, Franco D, Nanni JC. et al. Control of an outbreak of postoperative bone mucormycosis: an intervention study of contiguous cohorts. Am J Infect Control 2016; 44 (12) 1715-1717
• 62 Walther G, Wagner L, Kurzai O. Outbreaks of Mucorales and the species involved. Mycopathologia 2020; 185 (05) 765-781
• 63 Limper AH, Knox KS, Sarosi GA. et al; American Thoracic Society Fungal Working Group. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011; 183 (01) 96-128
• 64 Miller R, Assi M. AST Infectious Diseases Community of Practice. Endemic fungal infections in solid organ transplant recipients-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33 (09) e13553
• 65 Kauffman CA, Freifeld AG, Andes DR. et al. Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET). Transpl Infect Dis 2014; 16 (02) 213-224
• 66 Thomas Jr CF, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004; 350 (24) 2487-2498
• 67 Wieruszewski PM, Barreto EF, Barreto JN. et al. Preadmission corticosteroid therapy and the risk of respiratory failure in adults without HIV presenting with Pneumocystis pneumonia. J Intensive Care Med 2020; 35 (12) 1465-1470
• 68 Nield B, Larsen SR, van Hal SJ. Clinical experience with new formulation SUBA®-itraconazole for prophylaxis in patients undergoing stem cell transplantation or treatment for haematological malignancies. J Antimicrob Chemother 2019; 74 (10) 3049-3055
• 69 Johnson MD, Lewis RE, Dodds Ashley ES. et al. Core recommendations for antifungal stewardship: a statement of the Mycoses Study Group Education and Research Consortium. J Infect Dis 2020; 222 (Suppl. 03) S175-S198
• 70 Shaw KJ, Ibrahim AS. Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections. J Fungi (Basel) 2020; 6 (04) 6
• 71 Astvad KMT, Jørgensen KM, Hare RK, Datcu R, Arendrup MC. Olorofim susceptibility testing of 1,423 Danish mold isolates obtained in 2018-2019 confirms uniform and broad-spectrum activity. Antimicrob Agents Chemother 2020; 65 (01) 65
• 72 Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A. In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies. J Antimicrob Chemother 2020; 75 (12) 3582-3585
• 73 Singh A, Singh P, Meis JF, Chowdhary A. In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species. J Antimicrob Chemother 2021; dkaa562
• 74 Brand SR, Sobel JD, Nyirjesy P. et al. Randomized phase 2 study of VT-1161 for the treatment of acute vulvovaginal candidiasis. Clin Infect Dis 2020; ciaa1204 . doi: 10.1093/cid/ciaa1204
• 75 Thompson GR, Soriano A, Skoutelis A. et al. Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis—The STRIVE trial. Clin Infect Dis 2020; ciaa1380 . doi: 10.1093/cid/ciaa1380
• 76 Miesel L, Cushion MT, Ashbaugh A, Lopez SR, Ong V. Efficacy of rezafungin in prophylactic mouse models of invasive Candidiasis, Aspergillosis, and Pneumocystis pneumonia. Antimicrob Agents Chemother 2021; 65 (03) e01992-20